Anders Jack 4

What Happened

• Anders Jack, Chief Financial Officer of Revolution Medicines (RVMD), disposed of 2,722 shares on June 16, 2026. The shares were sold (S) in an open-market/private sale at a weighted average price of $156.12, generating proceeds of $424,956. The filing indicates the sale was made under a pre-established Rule 10b5-1 instruction to satisfy tax withholding related to RSU vesting.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18 (timely).
• Shares sold: 2,722; weighted average price: $156.12; price range across trades: $156.1105–$156.8251.
• Proceeds reported: $424,956.
• Reason/footnote: Sold pursuant to a Rule 10b5-1 instruction letter adopted May 31, 2023 to satisfy the reporting person’s tax withholding obligation upon RSU vesting (Footnote F1).
• Filing notes it was executed in multiple trades and the filer will provide full trade-by-trade details on request (Footnote F2).
• Holdings called out in the filing: includes 51,388 RSUs (F3) and 479 ESPP shares acquired May 31, 2026 (F4). The filing does not state a single total "owned after" figure.

Context

• This sale was processed under a 10b5-1 plan for tax withholding related to RSUs, which is a common administrative transaction and does not necessarily indicate a change in insider sentiment. The filing appears timely (within the usual two-business-day Form 4 window).